Reaction Details |
| Report a problem with these data |
Target | Tyrosine-protein kinase Lck |
---|
Ligand | BDBM50329199 |
---|
Substrate/Competitor | n/a |
---|
Meas. Tech. | ChEMBL_674877 (CHEMBL1272506) |
---|
IC50 | 568±n/a nM |
---|
Citation | Belanger, DB; Williams, MJ; Curran, PJ; Mandal, AK; Meng, Z; Rainka, MP; Yu, T; Shih, NY; Siddiqui, MA; Liu, M; Tevar, S; Lee, S; Liang, L; Gray, K; Yaremko, B; Jones, J; Smith, EB; Prelusky, DB; Basso, AD Discovery of orally bioavailable imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors. Bioorg Med Chem Lett20:6739-43 (2010) [PubMed] Article |
---|
More Info.: | Get all data from this article, Assay Method |
---|
|
Tyrosine-protein kinase Lck |
---|
Name: | Tyrosine-protein kinase Lck |
Synonyms: | 2.7.10.2 | LCK | LCK_HUMAN | LSK | Leukocyte C-terminal Src kinase | Lymphocyte cell-specific protein-tyrosine kinase | Lymphocyte-specific protein tyrosine kinase | P56-LCK | Protein YT16 | Proto-oncogene Lck | Proto-oncogene tyrosine-protein kinase LCK | Src/Lck kinase | T cell-specific protein-tyrosine kinase |
Type: | n/a |
Mol. Mass.: | 57987.83 |
Organism: | Homo sapiens (Human) |
Description: | P06239 |
Residue: | 509 |
Sequence: | MGCGCSSHPEDDWMENIDVCENCHYPIVPLDGKGTLLIRNGSEVRDPLVTYEGSNPPASP
LQDNLVIALHSYEPSHDGDLGFEKGEQLRILEQSGEWWKAQSLTTGQEGFIPFNFVAKAN
SLEPEPWFFKNLSRKDAERQLLAPGNTHGSFLIRESESTAGSFSLSVRDFDQNQGEVVKH
YKIRNLDNGGFYISPRITFPGLHELVRHYTNASDGLCTRLSRPCQTQKPQKPWWEDEWEV
PRETLKLVERLGAGQFGEVWMGYYNGHTKVAVKSLKQGSMSPDAFLAEANLMKQLQHQRL
VRLYAVVTQEPIYIITEYMENGSLVDFLKTPSGIKLTINKLLDMAAQIAEGMAFIEERNY
IHRDLRAANILVSDTLSCKIADFGLARLIEDNEYTAREGAKFPIKWTAPEAINYGTFTIK
SDVWSFGILLTEIVTHGRIPYPGMTNPEVIQNLERGYRMVRPDNCPEELYQLMRLCWKER
PEDRPTFDYLRSVLEDFFTATEGQYQPQP
|
|
|
BDBM50329199 |
---|
n/a |
---|
Name | BDBM50329199 |
Synonyms: | 3-methyl-N-(6-methyl-3-(1H-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl)isothiazol-5-amine | CHEMBL1270796 |
Type | Small organic molecule |
Emp. Form. | C14H13N7S |
Mol. Mass. | 311.365 |
SMILES | Cc1cc(Nc2nc(C)cn3c(cnc23)-c2cn[nH]c2)sn1 |
Structure |
|